Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy.

Fankhauser, Christian Daniel; Sander, Sophia; Roth, Lisa; Gross, Oliver; Eberli, Daniel; Sulser, Tullio; Seifert, Burkhardt; Beyer, Jörg; Hermanns, Thomas (2018). Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy. British journal of cancer, 118(6), pp. 825-830. Nature Publishing Group 10.1038/bjc.2017.467

[img]
Preview
Text
2018 Br J Cancer Fankhauser.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-Share Alike (CC-BY-NC-SA).

Download (207kB) | Preview

BACKGROUND

The prognostic utility of systemic inflammatory markers has so far not been investigated in patients with metastatic testicular germ cell tumours (GCTs).

METHODS

International Germ Cell Cancer Cooperative Group (IGCCCG) risk groups and blood-based systemic inflammatory markers (haemoglobin, leukocytes, platelets (P), neutrophils (N), lymphocytes (L), C-reactive protein (CRP) and albumin) of 146 patients undergoing first-line chemotherapy for GCT were retrieved. In addition, N to L ratio (NLR), P to L ratio and the systemic immune-inflammation index (SII=N × P/L) were calculated. The prognostic ability of these markers for overall survival (OS) were assessed using regression analyses and Kaplan-Meier curves with log-rank tests.

RESULTS

In univariate Cox regression, low haemoglobin and albumin as well as high leukocytes, N, NLR, SII and CRP were associated with a shorter OS. In multivariable Cox regression analyses, high leukocyte (hazard ratio (HR) 1.274 (95% confidence interval (CI) 1.057-1.535); P=0.011) and N count (1.470 (1.092-1.980); P=0.011), higher NLR (84.5 (2.2-3193.4); P=0.017) and SII (12.15 (1.17-126.26); P=0.037) remained independent prognostic predictors for OS besides the IGCCCG risk groups.

CONCLUSIONS

Systemic inflammatory markers might have prognostic utility for patients with metastatic GCT. The planned IGCCCG update could be an opportunity to test these markers in a larger data set.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Beyer, Jörg

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0007-0920

Publisher:

Nature Publishing Group

Language:

English

Submitter:

Rebeka Gerber

Date Deposited:

19 Mar 2019 12:55

Last Modified:

05 Dec 2022 15:25

Publisher DOI:

10.1038/bjc.2017.467

PubMed ID:

29485982

BORIS DOI:

10.7892/boris.124933

URI:

https://boris.unibe.ch/id/eprint/124933

Actions (login required)

Edit item Edit item
Provide Feedback